MA27591A1 - Agonistes du recepteur du facteur de liberation 2 de la corticotropine. - Google Patents

Agonistes du recepteur du facteur de liberation 2 de la corticotropine.

Info

Publication number
MA27591A1
MA27591A1 MA27779A MA27779A MA27591A1 MA 27591 A1 MA27591 A1 MA 27591A1 MA 27779 A MA27779 A MA 27779A MA 27779 A MA27779 A MA 27779A MA 27591 A1 MA27591 A1 MA 27591A1
Authority
MA
Morocco
Prior art keywords
receptor agonists
release factor
corticotropin release
corticotropin
releasing factor
Prior art date
Application number
MA27779A
Other languages
English (en)
Inventor
Robert Joseph Isfort
Wieslaw Adam Mazur
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of MA27591A1 publication Critical patent/MA27591A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des dérivés isolés du facteur de libération de la corticotropine et des acides nucléiques codant pour ceux-ci, efficaces dans le traitement des troubles modulés par le récepteur du facteur 2 de libération de la corticotropine, tels que la dystrophie musculaire.
MA27779A 2002-01-16 2004-07-13 Agonistes du recepteur du facteur de liberation 2 de la corticotropine. MA27591A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US34911702P 2002-01-16 2002-01-16
US37633702P 2002-04-29 2002-04-29
US38889502P 2002-06-14 2002-06-14
US41198802P 2002-09-19 2002-09-19

Publications (1)

Publication Number Publication Date
MA27591A1 true MA27591A1 (fr) 2005-11-01

Family

ID=27617822

Family Applications (3)

Application Number Title Priority Date Filing Date
MA27780A MA27592A1 (fr) 2002-01-16 2004-07-13 Agonistes du recepteur du facteur de liberation 2 de la corticotropine.
MA27779A MA27591A1 (fr) 2002-01-16 2004-07-13 Agonistes du recepteur du facteur de liberation 2 de la corticotropine.
MA27778A MA27590A1 (fr) 2002-01-16 2004-07-13 Agonistes du recepteur du facteur de liberation 2 de la corticotropine.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA27780A MA27592A1 (fr) 2002-01-16 2004-07-13 Agonistes du recepteur du facteur de liberation 2 de la corticotropine.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA27778A MA27590A1 (fr) 2002-01-16 2004-07-13 Agonistes du recepteur du facteur de liberation 2 de la corticotropine.

Country Status (30)

Country Link
US (7) US6936585B2 (fr)
EP (4) EP1465921B1 (fr)
JP (3) JP4489434B2 (fr)
KR (3) KR100735586B1 (fr)
CN (3) CN1617887A (fr)
AR (3) AR038143A1 (fr)
AT (4) ATE362488T1 (fr)
AU (2) AU2003205197B2 (fr)
BR (3) BR0306826A (fr)
CA (3) CA2470731C (fr)
CY (1) CY1106133T1 (fr)
DE (4) DE60313845T2 (fr)
DK (2) DK1465923T3 (fr)
ES (4) ES2309909T3 (fr)
HK (1) HK1078095A1 (fr)
IL (5) IL162530A0 (fr)
MA (3) MA27592A1 (fr)
MX (3) MXPA04006885A (fr)
MY (1) MY140306A (fr)
NO (3) NO20043366L (fr)
NZ (3) NZ533598A (fr)
PE (3) PE20030747A1 (fr)
PL (3) PL371364A1 (fr)
PT (2) PT1465923E (fr)
RU (1) RU2294333C2 (fr)
SA (3) SA03230564A (fr)
SI (1) SI1465921T1 (fr)
TW (3) TWI300442B (fr)
WO (3) WO2003062268A2 (fr)
ZA (1) ZA200404995B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1319024A2 (fr) * 2000-09-22 2003-06-18 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Methodes permettant d'ameliorer les proprietes antagonistes/agonistes des antagonistes/agonistes peptidiques du recepteur de la corticoliberine (crfr)
US6936585B2 (en) * 2002-01-16 2005-08-30 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists
WO2005103690A2 (fr) * 2004-04-24 2005-11-03 Bayer Healthcare Ag Diagnostic et therapeutique de maladies associees au recepteur de l'hormone de liberation de la corticotropine 2 (crhr2)
CA2602665A1 (fr) * 2005-03-30 2006-10-19 Novartis Vaccines And Diagnostics, Inc. Haemophilus influenzae de type b
US7815905B2 (en) 2006-01-27 2010-10-19 Research Development Foundation Methods of increasing insulin sensitivity or decreasing insulin secretion by administering corticotropin releasing factor receptor-2 inhibitors
US20100197586A1 (en) * 2007-09-11 2010-08-05 Dorian Bevec Use of secretin and optionally urodilatin as therapeutic agents
WO2009043469A2 (fr) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009046874A1 (fr) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Polythérapie de peptide potentialisateur de la trh et de stresscopine
US10040838B2 (en) * 2008-11-04 2018-08-07 Janssen Pharmaceutica Nv CRHR2 peptide agonists and uses thereof
EP2206726A1 (fr) * 2009-01-08 2010-07-14 Universite Joseph Fourier Outils non invasifs pour la détection de plaques athérosclérotique vulnérables
JP2013510167A (ja) * 2009-11-04 2013-03-21 ヤンセン ファーマシューティカ エヌ．ベー． ストレスコピン様ペプチドによる心不全の治療方法
WO2013063046A1 (fr) 2011-10-24 2013-05-02 Research Development Foundation Procédés d'augmentation de la sécrétion d'insuline par costimulation des récepteurs du facteur de libération de la corticotropine
EP2814513B1 (fr) * 2012-02-14 2017-12-20 The Regents of The University of California Administration systémique et expression régulée des gènes à action paracrine pour les maladies cardiovasculaires et autres états
JOP20170153A1 (ar) 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
MX2019004401A (es) * 2016-10-20 2019-09-26 Cortene Inc Metodos de tratamiento y enfermedades resultantes de una respuesta de tension mal adaptada.
CN110755434B (zh) * 2018-07-27 2022-03-15 中国医学科学院药物研究所 化合物palosuran防治骨骼肌萎缩等疾病的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5235036A (en) 1991-05-31 1993-08-10 The Salk Institute For Biological Studies Crf analogs
US5786203A (en) 1994-06-14 1998-07-28 Neurocrine Biosciences, Inc. Isolated nucleic acid encoding corticotropin-releasing factor2 receptors
EP0860501A3 (fr) 1994-06-14 1999-05-19 Neurocrine Biosciences, Inc. Récepteurs du facteur 2 libérant la corticotropine
US5663292A (en) 1994-12-12 1997-09-02 The Salk Institute For Biological Studies Cyclic CRF analogs
US5824771A (en) 1994-12-12 1998-10-20 The Salk Institute For Biological Studies Cyclic CRF agonists
US5660824A (en) 1995-05-24 1997-08-26 Grabstein; Kenneth H. Muscle trophic factor
AU6277796A (en) 1995-06-13 1997-01-15 Salk Institute For Biological Studies, The Urocortin peptides
US5869450A (en) 1996-03-06 1999-02-09 The Regents Of The University Of California Anti-inflammatory compositions and method with corticotropin-releasing factor analogs
WO2002012307A1 (fr) 2000-08-04 2002-02-14 Research Development Foundation Proteines urocortines et utilisations
US20020082409A1 (en) 2000-10-26 2002-06-27 Hsu Sheau Yu Stresscopins and their uses
US6670140B2 (en) * 2001-03-06 2003-12-30 The Procter & Gamble Company Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
US6936585B2 (en) * 2002-01-16 2005-08-30 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists

Also Published As

Publication number Publication date
MA27592A1 (fr) 2005-11-01
KR100758858B1 (ko) 2007-09-14
IL196384A0 (en) 2011-07-31
AU2003205197B2 (en) 2006-03-02
ATE383372T1 (de) 2008-01-15
CA2470656A1 (fr) 2003-07-31
TW200302276A (en) 2003-08-01
EP1465921A2 (fr) 2004-10-13
RU2294333C2 (ru) 2007-02-27
US7462597B2 (en) 2008-12-09
EP1465922B1 (fr) 2008-01-09
MXPA04006885A (es) 2004-12-06
US20030148957A1 (en) 2003-08-07
ATE362488T1 (de) 2007-06-15
BR0306878A (pt) 2004-10-26
BR0306826A (pt) 2005-09-06
IL162529A0 (en) 2005-11-20
HK1078095A1 (en) 2006-03-03
CY1106133T1 (el) 2011-06-08
CN100475844C (zh) 2009-04-08
DE60313845D1 (de) 2007-06-28
EP1724283A2 (fr) 2006-11-22
IL197774A0 (en) 2009-12-24
JP4508648B2 (ja) 2010-07-21
TW200302278A (en) 2003-08-01
DE60307044T2 (de) 2007-02-15
EP1465921B1 (fr) 2006-07-26
PE20030849A1 (es) 2003-12-01
DE60318547D1 (de) 2008-02-21
WO2003062277A1 (fr) 2003-07-31
ES2287484T3 (es) 2007-12-16
KR20040082390A (ko) 2004-09-24
US7608701B2 (en) 2009-10-27
WO2003062268A3 (fr) 2003-11-27
WO2003062268A2 (fr) 2003-07-31
PE20030747A1 (es) 2003-10-23
DK1465923T3 (da) 2007-07-02
EP1465923B1 (fr) 2007-05-16
CA2470731C (fr) 2011-06-21
TW200302277A (en) 2003-08-01
US20090124793A1 (en) 2009-05-14
NZ533600A (en) 2007-02-23
US20030148956A1 (en) 2003-08-07
CA2470743A1 (fr) 2003-07-31
SA03230564A (ar) 2005-12-03
ES2309909T3 (es) 2008-12-16
KR100758857B1 (ko) 2007-09-14
NO20043371L (no) 2004-10-06
EP1465923A1 (fr) 2004-10-13
MXPA04006883A (es) 2004-12-06
KR20040082389A (ko) 2004-09-24
DK1465921T3 (da) 2006-11-27
ATE398632T1 (de) 2008-07-15
CN1617885A (zh) 2005-05-18
NZ533599A (en) 2007-03-30
PL373529A1 (en) 2005-09-05
AR038143A1 (es) 2004-12-29
NO20043396L (no) 2004-10-06
WO2003062269A3 (fr) 2003-11-06
PL371364A1 (en) 2005-06-13
US20030148958A1 (en) 2003-08-07
ES2269976T3 (es) 2007-04-01
DE60321730D1 (de) 2008-07-31
AR038142A1 (es) 2004-12-29
US20080004435A1 (en) 2008-01-03
NZ533598A (en) 2007-03-30
NO20043366L (no) 2004-10-06
MA27590A1 (fr) 2005-11-01
ATE334147T1 (de) 2006-08-15
SA03230565B1 (ar) 2006-10-31
PT1465921E (pt) 2006-12-29
US6936585B2 (en) 2005-08-30
SI1465921T1 (sl) 2006-10-31
JP2005522191A (ja) 2005-07-28
JP4508649B2 (ja) 2010-07-21
TWI300442B (en) 2008-09-01
US7192923B2 (en) 2007-03-20
SA03230565A (ar) 2005-12-03
US7897731B2 (en) 2011-03-01
SA03230564B1 (ar) 2006-10-31
PE20030974A1 (es) 2003-12-26
AU2003237419B2 (en) 2006-04-13
IL162431A0 (en) 2005-11-20
JP2005525101A (ja) 2005-08-25
JP2005521387A (ja) 2005-07-21
ZA200404995B (en) 2005-06-29
CA2470656C (fr) 2011-06-28
CN100391972C (zh) 2008-06-04
PL373139A1 (en) 2005-08-22
EP1724283A3 (fr) 2007-04-11
CA2470731A1 (fr) 2003-07-31
EP1465922A2 (fr) 2004-10-13
IL162530A0 (en) 2005-11-20
ES2299701T3 (es) 2008-06-01
DE60318547T2 (de) 2008-12-24
US20060025339A1 (en) 2006-02-02
US7192924B2 (en) 2007-03-20
US7632933B2 (en) 2009-12-15
DE60313845T2 (de) 2008-01-31
CN1617886A (zh) 2005-05-18
PT1465923E (pt) 2007-08-06
KR100735586B1 (ko) 2007-07-04
WO2003062269A2 (fr) 2003-07-31
RU2004124847A (ru) 2005-04-20
CA2470743C (fr) 2011-12-13
US20100197579A1 (en) 2010-08-05
DE60307044D1 (de) 2006-09-07
MXPA04006884A (es) 2004-12-06
CN1617887A (zh) 2005-05-18
AR038144A1 (es) 2004-12-29
KR20040082392A (ko) 2004-09-24
JP4489434B2 (ja) 2010-06-23
BR0306838A (pt) 2005-04-05
EP1724283B1 (fr) 2008-06-18
MY140306A (en) 2009-12-31

Similar Documents

Publication Publication Date Title
MA27591A1 (fr) Agonistes du recepteur du facteur de liberation 2 de la corticotropine.
MA27334A1 (fr) Utilisation d'inhibiteurs de l'ikb kinase dans le traitement de la douleur
MA29692B1 (fr) Derives de la xanthine en tant qu'agonistes selectifs du hm74a
BRPI0414435A (pt) métodos e reagentes para o tratamento de distúrbios imunoinflamatórios
CY1108706T1 (el) Ανοσορυθμιστης
MA27509A1 (fr) Formulations a liberation prolongee contenant de la lamotrigine
TR200102021T2 (tr) TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları
TNSN98017A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant.
BR9812753A (pt) Combinação farmacêutica, uso da mesma, processo para tratamento de uma doença inflamatória, e, composição farmacêutica
CY1108274T1 (el) Μακροβιο ομοιαζον με γλυκογονο πεπτιδιο 2 (glp-2) για την θεραπεια γαστρεντερικων ασθενειων και διαταραχων
DE602004024572D1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
MA29444B1 (fr) Antagonistes npy, preparation et utilisations
MA27063A1 (fr) Derives d'acide acetique d'indane et leur utilisation en tant qu'agents therapeutiques, produits intermediaires, et leur methode de preparation
EA200500250A1 (ru) Аналоги тиомолибдата и их применение
RS51540B (en) MEMANTINE FOR THE TREATMENT OF Mild to Moderate Alzheimer's Disease
MA31198B1 (fr) Nouvelle forme dosifiee
MY124786A (en) Bis-arylsulfones
DK1082131T3 (da) Immunoregulator
MA29133B1 (fr) Nouvelle combinaison
DE60226906D1 (de) 3,6-disubstituierte azabicyclo ä3.1.0ühexanderivate, die sich als muscarinrezeptorantagonisten eignen
BR9814867A (pt) Método para tratar discinesias relacionadas a doenças ou induzidas por drogas
FR2835851B1 (fr) Composition pour le traitement d'alliages de magnesium
BR0215366A (pt) Formulações transdérmicas adesivas de diclofenac sódico
FR2848452B1 (fr) Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
BR9913348A (pt) Tratamento dos distúrbios da ansiedade